Stay updated on Atrasentan in IgA Nephropathy Clinical Trial
Sign up to get notified when there's something new on the Atrasentan in IgA Nephropathy Clinical Trial page.

Latest updates to the Atrasentan in IgA Nephropathy Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check24 days agoChange DetectedUpdated the revision label from v3.0.2 to v3.2.0, indicating a newer version has been released. No other content changes observed.SummaryDifference0.1%

- Check25 days agoChange DetectedVersion update: from v3.0.2 to v3.1.0, with no other content changes.SummaryDifference0.1%

- Check32 days agoChange DetectedRemoved explicit mentions of Drug Safety, Counterfeit Drugs, Pharmaceutical Preparations, and Substandard Drugs; overall content framing in the safety/quality area appears diminished.SummaryDifference0.2%

- Check39 days agoChange DetectedUpdated version from v3.0.1 to v3.0.2; removed the Back to Top element. No changes to core content.SummaryDifference0.1%

- Check47 days agoChange DetectedThe web page has been updated from version 3.0.0 to 3.0.1, indicating a revision in the content. There are no significant changes in core content, names, pricing, or availability.SummaryDifference0.1%

- Check54 days agoChange DetectedThe webpage has undergone significant updates, including the addition of new facility names and locations, as well as updated publications related to IgA nephropathy. Notably, several previously listed locations and related medical topics have been removed.SummaryDifference14%

Stay in the know with updates to Atrasentan in IgA Nephropathy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Atrasentan in IgA Nephropathy Clinical Trial page.